微信公众号

官网二维码
中国癌症防治杂志

中国癌症防治杂志 ›› 2011, Vol. 3 ›› Issue (4): 315-318.doi: 10.3969/j.issn.1674-5671.2011.04.13

• 临床研究 • 上一篇    下一篇

希罗达联合长春瑞宾二线治疗紫杉类及蒽环类失败复发转移性乳腺癌的疗效观察

陆永奎, 谢伟敏, 周文献, 胡晓桦, 谭晓虹, 廖小莉, 刘志辉, 李永强, 岑洪   

  1. 广西医科大学附属肿瘤医院化疗五科
  • 出版日期:2011-12-25 发布日期:2012-01-20

Effect of capecitabine combined with vinorelbine on treating the patients with relapsed and metastatic breast cancer

LU Yong-Kui, XIE Wei-Min, ZHOU Wen-Xian, HU Xiao-Hua, TAN Xiao-Hong, LIAO Xiao-Li, LIU Zhi-Hui, LI Yong-Qiang, CEN Hong   

  • Online:2011-12-25 Published:2012-01-20

PDF (PC)

598

赞

被引次数

15

摘要： 目的 观察希罗达联合长春瑞宾二线治疗复发转移乳腺癌的临床效果及不良反应发生情况。方法 选择32例乳腺癌复发转移性患者，于第1、8天静脉滴注长春瑞宾25mg／m2；早晚2次口服希罗达2000mg／(m2·d)，连用2周，休息l周为1个周期。所有患者均行2个以上周期的治疗。结果32例患者中，5例完全缓解(CR)，12例部分缓解(PR)，l1例病情稳定(SD)，4例病情进展(PD)，总有效率53.12% ，临床获益患者(CR +PR +SD)28例(87.5%)。患者不良反应为恶心、呕吐、皮肤色素沉着、厌食、手足综合征和疲劳等，小部分患者有头晕、口腔炎、胸闷和腹泻发生，偶见谷丙转氨酶、胆红素轻度升高者，其中轻～中度白细胞下降及贫血者占36.4%。结论 对紫杉类及蒽环类治疗失败的复发转移乳腺癌患者，希罗达联合长春瑞宾作为二线治疗方案治疗效果肯定，且不良反应轻，患者能耐受。

关键词:  乳腺癌, 长春瑞宾, 希罗达, 化疗

Abstract: Objectives To evaluate the effect and adverse reactions of capecitabine combined with vinorelbine on treating the recurrent and metastatic breast cancer that failed to the treatment of taxanes and anthracycline. Methods Thirty-two patients with recurrent or metastatic breast cancer were treated by capecitabine and vinorelbine.Vinorelbine was given at the dose of 25mg/m2 on day 1st and day 8th，and xeloda was given at the dose of 2 000mg/m2/d，twice a day for two weeks followed by one week of rest as a cycle. All patients were treated with two or more cycles.Results Among the 32 patients，five achieved complete response，12 achieved partial response. The total response rate was 53.1%，and the clinical benefit response (CR+PR+SD) was 87.5%.The common adverse reactions were hand-foot syndrome，skin pigmentation，nausea，vomiting，anorexia and fatigue.Mild moderate anemia and leukopenia were observed in 36.4% of patients. Mild elevation of total bilirubin and alanine transaminase (ALT) occurred in a few patients. Conclusion Capecitabine combined with vinorelbine is an effective ragmen for treating patients with relapsed and metastatic breast cancer，especially for those who have failed to chemotherapy with anthracycline and taxanes. The regimen is tolerable while has mild adverse reactions.

Key words: Breast cancer, Capecitabine, Vinorelbine, Chemotherapy